Yahoo
NasdaqGS - Nasdaq Real Time Price USD

ICU Medical, Inc. (ICUI)

168.47 +2.08 (+1.25%)
As of 11:27:42 AM EDT. Market Open.
Trade ICUI on Coinbase
Chart Range Bar
Loading chart for ICUI
  • Previous Close 166.39
  • Open 168.85
  • Bid 120.06 x 200
  • Ask 215.42 x 200
  • Day's Range 166.43 - 168.85
  • 52 Week Range 113.37 - 192.85
  • Volume 26,867
  • Avg. Volume 265,048
  • Market Cap (intraday) 4.213B
  • Beta (5Y Monthly) 0.87
  • PE Ratio (TTM) 141.57
  • EPS (TTM) 1.19
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 193.38
  • Morningstar Rating Rating available with Stock Picks access

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

www.icumed.com

13,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ICUI
18.08%
S&P 500 (^GSPC)
12.91%

1-Year Return

ICUI
43.17%
S&P 500 (^GSPC)
12.17%

3-Year Return

ICUI
69.18%
S&P 500 (^GSPC)
87.72%

5-Year Return

ICUI
28.04%
S&P 500 (^GSPC)
67.83%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 547.88M
Earnings 19.09M
Profit Margin 3.48%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
100M
200M
300M
400M
500M
-2.0%
0.0%
2.0%
4.0%

Analyst Insights

View More

Analyst Price Targets

178.00
193.38 Average
168.47 Current
210.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/7/2026
Analyst Piper Sandler
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 163 -> 195

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.39%

  • Return on Assets (ttm)

    1.93%

  • Return on Equity (ttm)

    1.41%

  • Revenue (ttm)

    2.16B

  • Net Income Avi to Common (ttm)

    30.09M

  • Diluted EPS (ttm)

    1.19

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    302.64M

  • Total Debt/Equity (mrq)

    59.82%

  • Levered Free Cash Flow (ttm)

    163.56M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: